BRAF and melanoma: Such results may also have therapeutic implications in the future, since BRAF inhibitors vemurafenib and dabrafenib are currently FDA approved for the treatment of late-stage melanoma (see below), and might be tested in patients with corticotroph cells harboring BRAF V600E in recurrent CD (60).